[go: up one dir, main page]

DK0985039T3 - Kunstige antistof-polypeptider - Google Patents

Kunstige antistof-polypeptider

Info

Publication number
DK0985039T3
DK0985039T3 DK98930131T DK98930131T DK0985039T3 DK 0985039 T3 DK0985039 T3 DK 0985039T3 DK 98930131 T DK98930131 T DK 98930131T DK 98930131 T DK98930131 T DK 98930131T DK 0985039 T3 DK0985039 T3 DK 0985039T3
Authority
DK
Denmark
Prior art keywords
polypeptide
monobody
uncat
cat
identifying
Prior art date
Application number
DK98930131T
Other languages
Danish (da)
English (en)
Inventor
Shohei Koide
Original Assignee
Novartis Int Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Int Pharm Ltd filed Critical Novartis Int Pharm Ltd
Application granted granted Critical
Publication of DK0985039T3 publication Critical patent/DK0985039T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1044—Preparation or screening of libraries displayed on scaffold proteins
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/78—Thyroid gland hormones, e.g. T3, T4, TBH, TBG or their receptors

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK98930131T 1997-06-12 1998-06-12 Kunstige antistof-polypeptider DK0985039T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4941097P 1997-06-12 1997-06-12
PCT/US1998/012099 WO1998056915A2 (en) 1997-06-12 1998-06-12 Artificial antibody polypeptides

Publications (1)

Publication Number Publication Date
DK0985039T3 true DK0985039T3 (da) 2008-06-09

Family

ID=21959681

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98930131T DK0985039T3 (da) 1997-06-12 1998-06-12 Kunstige antistof-polypeptider

Country Status (10)

Country Link
US (11) US6673901B2 (ja)
EP (3) EP0985039B1 (ja)
JP (1) JP3614866B2 (ja)
AT (1) ATE386802T1 (ja)
AU (1) AU729035B2 (ja)
CA (1) CA2293632C (ja)
DE (1) DE69839147T2 (ja)
DK (1) DK0985039T3 (ja)
ES (1) ES2301198T3 (ja)
WO (1) WO1998056915A2 (ja)

Families Citing this family (630)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
AUPP221098A0 (en) * 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
PT1133558E (pt) 1998-11-27 2007-01-31 Ucb Sa Composições e métodos para aumentar a mineralização óssea
US6818418B1 (en) * 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en) * 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
JP4562286B2 (ja) * 1998-12-10 2010-10-13 ブリストル−マイヤーズ スクウィブ カンパニー 抗体模倣物および他の結合タンパク質のタンパク質骨格
DE19932688B4 (de) * 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
AU2001277867B2 (en) 2000-07-11 2006-12-07 Research Corporation Technologies, Inc. Artificial antibody polypeptides
AU1325102A (en) * 2000-10-16 2002-04-29 Phylos Inc Protein scaffolds for antibody mimics and other binding proteins
US7598352B2 (en) * 2000-11-17 2009-10-06 University Of Rochester Method of identifying polypeptide monobodies which bind to target proteins and use thereof
CA2443332A1 (en) * 2001-04-04 2002-10-17 University Of Rochester .alpha..nu..beta.3 integrin-binding polypeptide monobodies and their use
US20050037427A1 (en) * 2001-12-10 2005-02-17 Erwin Houtzager Structure for presenting desired peptide sequences
US20030215914A1 (en) * 2001-12-10 2003-11-20 Erwin Houtzager Structure for presenting desired peptide sequences
EP1318195A1 (en) * 2001-12-10 2003-06-11 CatchMabs B.V. A structure for presenting desired peptide sequences
EP1461001A4 (en) * 2002-01-03 2010-03-31 Scripps Research Inst ASSOCIATED WITH CANCER EPITOP
WO2003061570A2 (en) * 2002-01-16 2003-07-31 Zyomyx, Inc. Engineered binding proteins
US6936427B2 (en) * 2002-02-08 2005-08-30 Trellis Bioscience, Inc. Real time detection of intermolecular interaction
WO2003087763A2 (en) 2002-04-03 2003-10-23 Celltech R & D, Inc. Association of polymorphisms in the sost gene region with bone mineral density
US7357928B2 (en) * 2002-04-08 2008-04-15 University Of Louisville Research Foundation, Inc. Method for the diagnosis and prognosis of malignant diseases
US7541150B2 (en) * 2002-04-08 2009-06-02 University Of Louisville Research Foundation, Inc Method for the diagnosis and prognosis of malignant diseases
AU2003243436A1 (en) 2002-06-06 2003-12-22 Shohei Koide Reconstituted polypeptides
JP2005530515A (ja) * 2002-06-26 2005-10-13 ユニヴァーシティー オヴ ルイスヴィル リサーチ ファウンデイション インコーポレイテッド アポトーシスの検出方法
US20050074865A1 (en) 2002-08-27 2005-04-07 Compound Therapeutics, Inc. Adzymes and uses thereof
US7083948B1 (en) 2002-12-24 2006-08-01 Immunex Corporation Polypeptide purification reagents and methods for their use
US7196715B2 (en) * 2003-01-17 2007-03-27 Hewlett-Packard Development Company, L.P. Speed control using drive current profile
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
DE10324447A1 (de) * 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
NZ544618A (en) * 2003-06-16 2009-02-28 Celltech R & D Inc Antibodies specific for sclerostin and methods for increasing bone mineralization
US20040266993A1 (en) * 2003-06-30 2004-12-30 Evans Glen A. Non-immunoglobulin binding polypeptides
TR200600945T1 (tr) * 2003-09-05 2006-10-26 The Scripps Research Institute Terapötik usuller.
JP2007504250A (ja) * 2003-09-05 2007-03-01 ザ スクリプス リサーチ インスティテュート コレステロールオゾン化生成物の検出
AU2004296376B2 (en) 2003-12-05 2010-03-04 Bristol-Myers Squibb Company Inhibitors of type 2 vascular endothelial growth factor receptors
US20080220049A1 (en) * 2003-12-05 2008-09-11 Adnexus, A Bristol-Myers Squibb R&D Company Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins
CA2558740A1 (en) * 2004-03-03 2005-10-13 F. Hoffmann-La Roche Ag Method for the purification of an n-terminal fragment of hepatocyte growth factor
US7604947B2 (en) * 2004-06-09 2009-10-20 Cornell Research Foundation, Inc. Detection and modulation of cancer stem cells
DE102004049479A1 (de) * 2004-10-11 2006-04-13 Scil Proteins Gmbh Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie
ES2320374T3 (es) 2005-01-05 2009-05-21 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. Dominios de inmunoglobulina sintetica con propiedades de enlace modificadas en regiones de la molecula diferentes de las regiones de determinacion de complementariedad.
ITMI20050739A1 (it) * 2005-04-22 2006-10-23 Effebi Spa Piastrina di connsessione valvola-attuatore
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
JP2010507099A (ja) * 2006-10-16 2010-03-04 ザ アリゾナ ボード オブ リージェンツ ア ボディ コーポレイト オブ ザ ステイト オブ アリゾナ アクティング フォー アンド オン ビハーフ オブ アリゾナ ステイト ユニバーシティー 合成抗体
US7754213B2 (en) 2006-10-19 2010-07-13 Merck & Co., Inc. High affinity antibody antagonists of interleukin-13 receptor alpha 1
US20100015665A1 (en) * 2006-11-10 2010-01-21 Ucb Pharma S.A. Antibodies and diagnostics
US20100036091A1 (en) * 2006-11-10 2010-02-11 Amgen Inc. Antibody-based diagnostics and therapeutics
EP1925664A1 (en) * 2006-11-15 2008-05-28 Scil proteins GmbH Artificial binding proteins based on a modified alpha helical region of ubiquitin
AU2007325838B2 (en) * 2006-11-22 2013-09-19 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
CN101668771B (zh) * 2007-03-12 2013-08-21 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 单链抗体的基于序列的工程改造和最优化
PL2158315T3 (pl) 2007-06-25 2016-10-31 Sposoby modyfikowania przeciwciał i zmodyfikowane przeciwciała o ulepszonych właściwościach funkcjonalnych
PL2164961T3 (pl) * 2007-06-25 2015-08-31 Esbatech Alcon Biomed Res Unit Oparta na sekwencjach inżynieria i optymalizacja przeciwciał jednołańcuchowych
JP5602625B2 (ja) 2007-06-26 2014-10-08 エフ−スター ビオテヒノロギッシェ フォルシュングス− ウント エントヴィッケルングスゲゼルシャフト ミット ベシュレンクテル ハフツング 結合物質のディスプレイ
WO2009018386A1 (en) 2007-07-31 2009-02-05 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
JP5781762B2 (ja) * 2007-08-10 2015-09-24 プロテリックス、インク ユニバーサルｉｉｉ型フィブロネクチン結合ドメインのライブラリ
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
GB2453589A (en) 2007-10-12 2009-04-15 King S College London Protease inhibition
BRPI0818810A2 (pt) 2007-10-31 2014-10-29 Medimmune Llc Esqueletos d polipeptídeo recombinante e multimérico, molécula de ácido n ucleico isolado, vetor de expressão, célula hospedeira, biblioteca de exibição de polipeptídeo, coleção de moléculas de ácido nucleico isolado, métodos para obter um esqueleto de polipeptídeo e pelo menos dois esqueletos, para detectar um composto em uma amostra, para capturar um composto em uma amostra, para prevenir, tratar, controlar ou melhorar uma doença, para diagnose ou formação de imagem de uma doença para purificar e produzir um esqueleto, para ensaiar ou detectar a ligação de um esqueleto a um alvo, para usar o esqueleto e para prevenir, tratar, melhora ou controlar câncer, composição estéril, isenta de pirógeno, composição farmacêutica, e, processo escalável.
ES2663077T3 (es) 2007-11-02 2018-04-11 Novartis Ag Moléculas y métodos de modulación de la proteína 6 relacionada con el receptor de lipoproteína de baja densidad (lrp6)
EP2215115A1 (en) 2007-11-08 2010-08-11 The University of Chicago Molecular affinity clamp technology and uses thereof
KR101377535B1 (ko) 2007-11-16 2014-03-27 더 락커펠러 유니버시티 원섬유 형태의 베타­아밀로이드 단백질에 대해 특이적인 항체
CN101896201A (zh) * 2007-12-14 2010-11-24 安进公司 使用抗硬骨素抗体治疗骨折的方法
EP2231181B1 (en) 2007-12-17 2016-02-17 Marfl AB New vaccine for the treatment of mycobacterium related disorders
WO2009088837A2 (en) * 2007-12-31 2009-07-16 The University Of Louisville Research Foundation, Inc. Methods and products to target, capture and characterize stem cells
WO2009102421A2 (en) 2008-02-14 2009-08-20 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind egfr
WO2009126031A1 (en) * 2008-04-10 2009-10-15 Fujifilm Manufacturing Europe B.V. Recombinant protein enriched in a heparin binding site and/or a heparan sulfate binding site
EA201001734A1 (ru) 2008-05-02 2011-10-31 Новартис Аг Улучшенные связывающие молекулы на основе фибронектина и их применение
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
PE20091931A1 (es) 2008-05-22 2009-12-31 Bristol Myers Squibb Co Proteinas de dominio de armazon basadas en fibronectina multivalentes
ES2884117T3 (es) 2008-06-25 2021-12-10 Novartis Ag Optimización de la solubilidad de inmunoaglutinantes
SI2328616T1 (sl) 2008-08-05 2015-08-31 Novartis Ag Sestavki in postopki za protitelesa proti komplementnemu proteinu C5
WO2010021718A1 (en) * 2008-08-19 2010-02-25 Nektar Therapeutics Complexes of small-interfering nucleic acids
SI2356269T1 (sl) 2008-10-31 2016-10-28 Janssen Biotech, Inc. Ogrodni sestavki, postopki in uporabe na osnovi domene fibronektina tipa III
US8415291B2 (en) * 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
ES2410579T5 (es) 2008-12-16 2021-10-04 Novartis Ag Sistemas de despliegue de levaduras
CA2752211C (en) * 2009-02-12 2020-03-24 Janssen Biotech, Inc. Fibronectin type iii domain based scaffold compositions, methods and uses
WO2010115932A1 (en) 2009-04-08 2010-10-14 Novartis Ag Combination for the treatment of bone loss
US8067201B2 (en) * 2009-04-17 2011-11-29 Bristol-Myers Squibb Company Methods for protein refolding
WO2010124113A1 (en) 2009-04-23 2010-10-28 Infinity Pharmaceuticals, Inc. Anti-fatty acid amide hydrolase-2 antibodies and uses thereof
US9133500B2 (en) 2009-08-10 2015-09-15 MorphoSys A6 Screening strategies for the identification of binders
EP3434769B1 (en) 2009-10-30 2020-11-25 Novartis AG Universal fibronectin type iii bottom-side binding domain libraries
WO2011051466A1 (en) * 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
JP6174320B2 (ja) 2009-11-17 2017-08-02 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント ヒトヌクレオリンに対するヒトモノクローナル抗体
DE102009047243A1 (de) 2009-11-27 2011-06-01 Orgentec Diagnostika Gmbh Monospezifische Polypeptidreagenzien
US20110150885A1 (en) 2009-12-11 2011-06-23 Atyr Pharma, Inc. Aminoacyl trna synthetases for modulating hematopoiesis
WO2011073214A2 (en) 2009-12-14 2011-06-23 Scil Proteins Gmbh A method for identifying hetero-multimeric modified ubiquitin proteins with binding capability to ligands
AU2010330794A1 (en) 2009-12-18 2012-06-21 Amgen Inc. Wise binding agents and epitopes
WO2012091756A1 (en) 2010-12-30 2012-07-05 Avidbiotics Corp. Non-natural mic proteins
WO2011092233A1 (en) 2010-01-29 2011-08-04 Novartis Ag Yeast mating to produce high-affinity combinations of fibronectin-based binders
ES2551871T3 (es) 2010-01-29 2015-11-24 Morphosys Ag Genotecas combinatorias de anticuerpos de roedor
WO2011100566A2 (en) 2010-02-12 2011-08-18 Oncomed Pharmaceuticals, Inc. Methods for identifying and isolating cells expressing a polypeptide
EP2533807A2 (en) * 2010-02-12 2012-12-19 University Of Rochester Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies
CN105175532B (zh) * 2010-04-13 2023-01-17 百时美施贵宝公司 结合pcsk9的基于纤连蛋白的支架域蛋白质
JP6041799B2 (ja) 2010-04-13 2016-12-14 メディミューン，エルエルシー Ｔｒａｉｌｒ２特異的多量体足場
WO2011128424A1 (en) 2010-04-16 2011-10-20 Novartis Ag Methods and compositions for improving implant osseointegration
US8980253B2 (en) 2010-04-26 2015-03-17 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase
US8961960B2 (en) 2010-04-27 2015-02-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases
US8993723B2 (en) 2010-04-28 2015-03-31 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl-tRNA synthetases
AU2011248490B2 (en) 2010-04-29 2016-11-10 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases
WO2011150279A2 (en) 2010-05-27 2011-12-01 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases
WO2011139907A2 (en) 2010-04-29 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
PL2571531T3 (pl) 2010-04-30 2016-12-30 Kompozycje stabilizowanych domen fibronektyny, sposoby i zastosowania
WO2011139986A2 (en) 2010-05-03 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases
US9034321B2 (en) 2010-05-03 2015-05-19 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
EP2566496B1 (en) 2010-05-03 2018-02-28 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases
US9062302B2 (en) 2010-05-04 2015-06-23 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-tRNA synthetase complex
SG185415A1 (en) 2010-05-06 2012-12-28 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
WO2011138392A1 (en) 2010-05-06 2011-11-10 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
CA3090304A1 (en) 2010-05-13 2011-11-17 Sarepta Therapeutics, Inc. Antisense modulation of interleukins 17 and 23 signaling
SMT202000095T1 (it) 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
AU2011252990B2 (en) 2010-05-14 2017-04-20 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-tRNA synthetases
CA2799480C (en) 2010-05-17 2020-12-15 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-trna synthetases
CN103180339B (zh) 2010-05-26 2016-04-27 百时美施贵宝公司 具有改善的稳定性的基于纤连蛋白的支架蛋白质
US20130157258A1 (en) 2010-06-15 2013-06-20 Vertex Pharmaceuticals Incorporated Hcv ns5b protease mutants
TW201217527A (en) 2010-07-09 2012-05-01 Biogen Idec Hemophilia Inc Processable single chain molecules and polypeptides made using same
WO2012021247A2 (en) 2010-07-12 2012-02-16 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases
JP5809687B2 (ja) 2010-07-14 2015-11-11 ジーンフロンティア株式会社 Ｒｎｆ８−ｆｈａドメイン改変タンパク質及びその製造方法
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
KR20130136443A (ko) 2010-07-30 2013-12-12 노파르티스 아게 피브로넥틴 크레이들 분자 및 그의 라이브러리
MY162825A (en) 2010-08-20 2017-07-31 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
AU2011293294B2 (en) 2010-08-25 2016-03-24 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Tyrosyl-tRNA synthetases
US20140308242A1 (en) 2010-10-21 2014-10-16 Vertex Pharmaceuticals Incorporated Biomarkers for hcv infected patients
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
KR20130133212A (ko) 2010-12-23 2013-12-06 인터셀 오스트리아 아게 입원 및 다른 환자에서 OprF/I 물질 및 이의 용도
MX2013010011A (es) 2011-03-01 2014-10-24 Amgen Inc Agentes de unión biespecífica.
EA029956B1 (ru) 2011-03-25 2018-06-29 Эмджен Инк. Кристаллы антител против склеростина и составы на их основе
US9469676B2 (en) 2011-04-13 2016-10-18 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
PL3404041T3 (pl) 2011-04-19 2020-12-14 Amgen Inc. Sposób leczenia osteoporozy
JP2014515759A (ja) 2011-04-29 2014-07-03 ノバルティス アーゲー 扁平上皮がんを治療する方法関連出願
EP2709669A1 (en) 2011-05-17 2014-03-26 Bristol-Myers Squibb Company Methods for maintaining pegylation of polypeptides
EP3318880B1 (en) 2011-05-17 2020-12-16 Bristol-Myers Squibb Company Improved methods for the selection of binding proteins
PT3446714T (pt) 2011-06-02 2021-06-23 Univ Louisville Res Found Inc Nanopartículas conjugadas a um agente antinucleolina
WO2012172495A1 (en) 2011-06-14 2012-12-20 Novartis Ag Compositions and methods for antibodies targeting tem8
US9492572B2 (en) 2011-06-15 2016-11-15 Scil Proteins Gmbh Dimeric binding proteins based on modified ubiquitins
WO2013019954A1 (en) 2011-08-04 2013-02-07 Amgen Inc. Method for treating bone gap defects
CA2849774C (en) * 2011-09-27 2020-01-07 Janssen Biotech, Inc. Fibronectin type iii repeat based protein scaffolds with alternative binding surfaces
HRP20201513T1 (hr) 2011-10-11 2020-12-11 Viela Bio, Inc. Cd40l-specifični tn3-izvedeni skeleti i postupci njihove uporabe
EP2766033B1 (en) 2011-10-14 2019-11-20 Novartis AG Antibodies and methods for wnt pathway-related diseases
EP2770823A4 (en) * 2011-10-28 2015-12-09 Trianni Inc TRANSGENIC ANIMALS AND METHOD FOR THEIR USE
CN104053670A (zh) 2011-10-31 2014-09-17 百时美施贵宝公司 具有降低的免疫原性的纤连蛋白结合域
WO2013070565A1 (en) 2011-11-07 2013-05-16 Medimmune, Llc Multispecific and multivalent binding proteins and uses thereof
IN2014CN04373A (ja) 2011-12-05 2015-09-04 Novartis Ag
TW201328706A (zh) 2011-12-05 2013-07-16 Novartis Ag 表皮生長因子受體３（ｈｅｒ３）之抗體
EP3330288A1 (en) 2011-12-21 2018-06-06 Novartis AG Compositions and methods for antibodies targeting factor p
SG10201509629QA (en) 2011-12-28 2015-12-30 Amgen Inc Method Of Treating Alveolar Bone Loss Through The Use Of Anti-Sclerostin Antibodies
KR102104686B1 (ko) 2012-01-10 2020-04-24 바이오젠 엠에이 인코포레이티드 뇌혈관 장벽을 통한 치료학적 분자의 수송 개선법
EP3311847A1 (en) 2012-02-16 2018-04-25 Atyr Pharma, Inc. Histidyl-trna synthetases for treating autoimmune and inflammatory diseases
WO2013144758A1 (en) 2012-03-27 2013-10-03 Novartis Ag Treatment of fibrosis
WO2013151649A1 (en) 2012-04-04 2013-10-10 Sialix Inc Glycan-interacting compounds
EP2657334B1 (en) 2012-04-26 2016-07-06 GeneFrontier Corporation Efficient method for displaying protein multimer
WO2013169734A1 (en) 2012-05-07 2013-11-14 Amgen Inc. Anti-erythropoietin antibodies
WO2013175276A1 (en) 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
WO2013184514A1 (en) 2012-06-04 2013-12-12 Irm Llc Site-specific labeling methods and molecules produced thereby
WO2014004549A2 (en) 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
JP6770312B2 (ja) 2012-07-05 2020-10-14 ユセベ ファルマ ソシエテ アノニム 骨疾患の治療
WO2014015217A1 (en) 2012-07-19 2014-01-23 Vertex Pharmaceuticals Incorporated Biomarkers for hcv infected patients
WO2014039775A1 (en) 2012-09-07 2014-03-13 Rutgers, The State University Of New Jersey Hiv-1 antigens with discrete conformational forms of the v1/v2 domain and methods of use thereof
SI3835310T1 (sl) 2012-09-13 2024-07-31 Bristol-Myers Squibb Company Proteini skafold domene na osnovi fibronektina, ki se vežejo na miostatin
WO2014047285A1 (en) 2012-09-19 2014-03-27 Paraskevi Giannakakou Identifying taxane sensitivity in prostate cancer patients
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
SMT201800624T1 (it) 2012-11-21 2019-01-11 Janssen Biotech Inc Anticorpi egfr/c-met bispecifici
WO2014084859A1 (en) 2012-11-30 2014-06-05 Novartis Ag Molecules and methods for modulating tmem16a activities
EP3851454A1 (en) 2012-12-05 2021-07-21 Novartis AG Compositions and methods for antibodies targeting epo
SG11201503566QA (en) 2012-12-18 2015-09-29 Novartis Ag Compositions and methods that utilize a peptide tag that binds to hyaluronan
WO2014118705A1 (en) 2013-01-31 2014-08-07 Novartis Ag Methods of treating chronic kidney disease-mineral and bone disorder using sclerostin antagonists
CN105431455A (zh) 2013-02-01 2016-03-23 圣塔玛丽亚生物疗法公司 抗激活素a化合物对受试者的施用
EP2951206A2 (en) 2013-02-01 2015-12-09 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
WO2014124017A1 (en) 2013-02-06 2014-08-14 Bristol-Myers Squibb Company Fibronectin type iii domain proteins with enhanced solubility
WO2014124258A2 (en) 2013-02-08 2014-08-14 Irm Llc Specific sites for modifying antibodies to make immunoconjugates
DK2953976T3 (da) 2013-02-08 2021-06-21 Novartis Ag Specifikke modificeringssteder i antistoffer til fremstilling af immunkonjugater
WO2014126884A1 (en) 2013-02-12 2014-08-21 Bristol-Myers Squibb Company High ph protein refolding methods
US20160025749A1 (en) 2013-03-11 2016-01-28 Amgen Inc. Protein formulations
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
CN105246916A (zh) 2013-03-14 2016-01-13 诺华股份有限公司 针对notch 3的抗体
EP3514178A1 (en) 2013-03-15 2019-07-24 Novartis AG Antibody drug conjugates
BR112015023752B1 (pt) 2013-03-15 2023-11-14 Zyngenia, Inc. Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
SG10201913874TA (en) 2013-03-15 2020-03-30 Biogen Ma Inc Factor ix polypeptide formulations
SG10201913751RA (en) 2013-05-06 2020-03-30 Scholar Rock Inc Compositions and methods for growth factor modulation
US9562101B2 (en) 2013-06-21 2017-02-07 Novartis Ag Lectin-like oxidized LDL receptor 1 antibodies and methods of use
AR096601A1 (es) 2013-06-21 2016-01-20 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
WO2015057545A2 (en) 2013-10-14 2015-04-23 Janssen Biotech, Inc. Cysteine engineered fibronectin type iii domain binding molecules
WO2015073878A1 (en) 2013-11-15 2015-05-21 Ur Diet, Llc Real-time satiety biofeedback
WO2015084994A1 (en) 2013-12-03 2015-06-11 President And Fellows Of Harvard College Methods and reagents for the assessment of gestational diabetes
AU2014363987A1 (en) 2013-12-09 2016-06-30 Janssen Biotech, Inc. Compositions and methods for phagocyte delivery of anti-staphylococcal agents
CN103698175B (zh) * 2013-12-09 2016-06-22 成都欧林生物科技股份有限公司 金黄色葡萄球菌疫苗成品的解离及含量测定方法和检测试剂盒
CN105899526A (zh) 2013-12-17 2016-08-24 诺华股份有限公司 细胞毒性肽和其缀合物
BR112016013187A2 (pt) 2013-12-19 2017-09-26 Novartis Ag receptores de antígenos quiméricos de mesotelina humanos e usos dos mesmos
US20150174242A1 (en) 2013-12-19 2015-06-25 Mayo Foundation For Medical Education And Research Monovalent anti-cd3 adjuvants
US10287354B2 (en) 2013-12-20 2019-05-14 Novartis Ag Regulatable chimeric antigen receptor
EP3097117B1 (en) 2014-01-21 2023-10-04 Novartis Ag Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
US20170073754A1 (en) 2014-02-07 2017-03-16 Novartis Ag Impact of genetic factors on disease progression and response to anti-c5 antibody in geographic atrophy
EP3129407A2 (en) 2014-03-12 2017-02-15 Novartis Ag Specific sites for modifying antibodies to make immunoconjugates
US20170081411A1 (en) 2014-03-15 2017-03-23 Novartis Ag Regulatable chimeric antigen receptor
WO2015142675A2 (en) 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
US10442851B2 (en) 2014-03-20 2019-10-15 Bristol-Myers Squibb Company Serum albumin-binding fibronectin type III domains
MX395149B (es) 2014-04-07 2025-03-24 Novartis Ag Terapias de combinación que comprenden un receptor quimérico de antígeno cd19 para el cáncer.
WO2015183938A1 (en) 2014-05-29 2015-12-03 Geneticure Llc Improved therapeutic regimen for hypertension
KR102503319B1 (ko) 2014-06-12 2023-02-28 라 파마슈티컬스 인코포레이티드 보체 활성의 조절
EA201692530A1 (ru) 2014-06-13 2017-07-31 Новартис Аг Цитотоксические пептиды и их конъюгаты
US20170327553A1 (en) 2014-06-25 2017-11-16 Novartis Ag Compositions and methods for long acting proteins
US20170290876A1 (en) 2014-06-25 2017-10-12 Novartis Ag Compositions and methods for long acting proteins
US20170209582A1 (en) 2014-06-26 2017-07-27 Amgen Inc. Protein formulations
CN106604932B (zh) 2014-07-10 2024-12-10 苏黎世大学 人白细胞介素-2的免疫刺激单克隆抗体
CN107257691B (zh) 2014-07-16 2021-09-21 达娜-法勃肿瘤研究所公司 低级别浆液性卵巢癌中的her3抑制
WO2016014530A1 (en) 2014-07-21 2016-01-28 Novartis Ag Combinations of low, immune enhancing. doses of mtor inhibitors and cars
MX2017001011A (es) 2014-07-21 2018-05-28 Novartis Ag Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
US9777061B2 (en) 2014-07-21 2017-10-03 Novartis Ag Treatment of cancer using a CD33 chimeric antigen receptor
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
US20170209492A1 (en) 2014-07-31 2017-07-27 Novartis Ag Subset-optimized chimeric antigen receptor-containing t-cells
PL3194968T3 (pl) 2014-08-01 2021-04-06 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Wykrywanie i traktowanie bydlęcego wirusa opryszczki
US10786578B2 (en) 2014-08-05 2020-09-29 Novartis Ag CKIT antibody drug conjugates
EP3177642B1 (en) 2014-08-07 2021-11-24 Novartis AG Angiopoietin-like 4 antibodies and methods of use
TW201613977A (en) 2014-08-07 2016-04-16 Novartis Ag Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
EA201790334A1 (ru) 2014-08-12 2017-06-30 Новартис Аг Конъюгаты анти-cdh6 антитела с лекарственным средством
JP6919118B2 (ja) 2014-08-14 2021-08-18 ノバルティス アーゲー ＧＦＲα−４キメラ抗原受容体を用いる癌の治療
US10287583B2 (en) 2014-08-15 2019-05-14 Adynxx, Inc. Oligonucleotide decoys for the treatment of pain
TW202140557A (zh) 2014-08-19 2021-11-01 瑞士商諾華公司 使用cd123嵌合抗原受體治療癌症
US20180010132A1 (en) 2014-09-11 2018-01-11 Novartis Ag Inhibition of prmt5 to treat mtap-deficiency-related diseases
KR20210149228A (ko) 2014-09-17 2021-12-08 노파르티스 아게 입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
CA2963935A1 (en) 2014-10-08 2016-04-14 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
EP3215519A1 (en) 2014-11-06 2017-09-13 Novartis AG Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase
US20170306046A1 (en) 2014-11-12 2017-10-26 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
JP6831783B2 (ja) 2014-11-14 2021-02-17 ノバルティス アーゲー 抗体薬物コンジュゲート
EP3227446A1 (en) 2014-12-01 2017-10-11 Novartis AG Compositions and methods for diagnosis and treatment of prostate cancer
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
CN111018987B (zh) 2014-12-05 2023-11-21 鸿运华宁（杭州）生物医药有限公司 一种能与人内皮素受体特异性结合的抗体及其应用
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
EP4036109A3 (en) 2014-12-29 2022-10-12 Novartis AG Methods of making chimeric antigen receptor-expressing cells
US9937222B2 (en) 2015-01-28 2018-04-10 Ra Pharmaceuticals, Inc. Modulators of complement activity
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
EP3253785B1 (en) 2015-02-06 2019-04-10 Navigo Proteins Gmbh Novel egfr binding proteins
US10683340B2 (en) 2015-03-12 2020-06-16 Medimmune, Llc Method of purifying albumin-fusion proteins
WO2016164580A1 (en) 2015-04-07 2016-10-13 Novartis Ag Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
CN119925616A (zh) 2015-04-08 2025-05-06 诺华股份有限公司 Cd20疗法、cd22疗法和与cd19嵌合抗原受体（car）表达细胞的联合疗法
CA2982996A1 (en) 2015-04-17 2016-10-20 David Maxwell Barrett Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
WO2016172583A1 (en) 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
EP3291839A1 (en) 2015-05-05 2018-03-14 The University of Louisville Research Foundation, Inc. Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and mri and/or x-ray contrast agents
HK1253005A1 (zh) 2015-05-06 2019-06-06 Janssen Biotech, Inc. 前列腺特异性膜抗原结合iii型纤连蛋白结构域
JP2018522540A (ja) 2015-06-05 2018-08-16 ノバルティス アーゲー 骨形成タンパク質９（ｂｍｐ９）を標的とする抗体およびそれらのための方法
US20180296537A1 (en) 2015-06-05 2018-10-18 Novartis Ag Methods and compositions for diagnosing, treating, and monitoring treatment of shank3 deficiency associated disorders
US10781246B2 (en) 2015-06-05 2020-09-22 New York University Compositions and methods for anti-staphylococcal biologic agents
US20190194315A1 (en) 2015-06-17 2019-06-27 Novartis Ag Antibody drug conjugates
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
WO2017009421A1 (en) 2015-07-16 2017-01-19 Scil Proteins Gmbh Novel immunoglobulin-binding proteins and their use in affinity purification
WO2017015119A1 (en) 2015-07-17 2017-01-26 The University Of Chicago Methods and composition for modifying enzymes
US10584152B2 (en) 2015-07-20 2020-03-10 Navigo Proteins Gmbh Binding proteins based on di-ubiquitin muteins and methods for generation
TWI859112B (zh) 2015-07-21 2024-10-21 瑞士商諾華公司 改良免疫細胞之功效及擴展之方法
CN108350072B (zh) 2015-08-03 2022-05-24 诺华股份有限公司 治疗fgf21相关病症的方法
CN108780084B (zh) 2015-09-03 2022-07-22 诺华股份有限公司 预测细胞因子释放综合征的生物标志物
AU2016320748B2 (en) 2015-09-09 2019-05-02 Novartis Ag Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies
EP3347377B1 (en) 2015-09-09 2021-02-17 Novartis AG Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
US9862760B2 (en) 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies
US10584160B2 (en) 2015-09-23 2020-03-10 Bristol-Myers Squibb Company Glypican-3-binding fibronectin based scaffold molecules
US10766946B2 (en) 2015-09-23 2020-09-08 Bristol-Myers Squibb Company Fast-off rate serum albumin binding fibronectin type III domains
JP7628764B2 (ja) 2015-09-29 2025-02-12 アムジエン・インコーポレーテツド Ａｓｇｒ阻害剤
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
CN108463248B (zh) 2015-11-12 2022-10-21 西雅图基因公司 聚糖相互作用化合物及使用方法
US10711282B2 (en) 2015-11-23 2020-07-14 Novartis Ag Optimized lentiviral transfer vectors and uses thereof
HK1257295A1 (zh) 2015-12-04 2019-10-18 Novartis Ag 用於免疫肿瘤学的组合物和方法
RS64067B1 (sr) 2015-12-16 2023-04-28 Ra Pharmaceuticals Inc Modulatori aktivnosti komplementa
CA3008102A1 (en) 2015-12-18 2017-06-22 Novartis Ag Antibodies targeting cd32b and methods of use thereof
EP3393504B1 (en) 2015-12-22 2025-09-24 Novartis AG Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
EP3397755B1 (en) 2015-12-28 2024-11-06 Novartis AG Methods of making chimeric antigen receptor -expressing cells
EP3397756B1 (en) 2015-12-30 2023-03-08 Novartis AG Immune effector cell therapies with enhanced efficacy
US11320422B2 (en) 2016-01-06 2022-05-03 Lonza Ltd. Inhibition of protein degradation for improved production
KR20180100224A (ko) 2016-01-11 2018-09-07 노바르티스 아게 인간 인터루킨-2에 대한 면역-자극 인간화 단일클론 항체, 및 이의 융합 단백질
BR112018013728A2 (pt) 2016-01-11 2018-12-18 Rubius Therapeutics Inc composições e métodos relacionados a sistemas celulares terapêuticos multimodais para indicações imunitárias
US20210198368A1 (en) 2016-01-21 2021-07-01 Novartis Ag Multispecific molecules targeting cll-1
TW201734041A (zh) 2016-02-19 2017-10-01 莫菲西斯公司 抗ｉｌ-１７ｃ抗體
MX2018010032A (es) 2016-02-23 2019-03-11 Sesen Bio Inc Formulaciones de antagonista de il-6 y sus usos.
KR20180118175A (ko) 2016-03-04 2018-10-30 노파르티스 아게 다중 키메라 항원 수용체 (car) 분자를 발현하는 세포 및 그에 따른 용도
EP3423578B1 (en) 2016-03-04 2020-04-29 MorphoSys AG Polypeptide library
US10689873B2 (en) 2016-03-10 2020-06-23 Lonza Ltd Customizable facility
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
CN118911486A (zh) 2016-03-10 2024-11-08 隆扎有限公司 可定制的设施
CN116284392A (zh) 2016-03-10 2023-06-23 艾科赛扬制药股份有限公司 活化素2型受体结合蛋白及其用途
WO2017165464A1 (en) 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
EP3445391B1 (en) 2016-04-13 2025-07-02 Vivia Biotech, S.L. Ex vivo bite-activated t cells
BR112018071107A2 (pt) 2016-04-14 2019-04-16 Lonza Ltd composições e métodos para a detecção de proteínas da célula hospedeira
WO2017181061A1 (en) 2016-04-15 2017-10-19 Ra Pharmaceuticals, Inc. Ras binding peptides and methods of use
JP7497955B6 (ja) 2016-04-15 2024-07-01 ノバルティス アーゲー 選択的タンパク質発現のための組成物および方法
AU2017252574B2 (en) 2016-04-22 2024-08-22 Acceleron Pharma Inc. ALK7 binding proteins and uses thereof
EP3448887A1 (en) 2016-04-27 2019-03-06 Novartis AG Antibodies against growth differentiation factor 15 and uses thereof
JP6959942B2 (ja) 2016-05-03 2021-11-05 ロンザ リミテッドLonza Limited タンパク質生成のための脂質代謝のモジュレーション
EP3452097A1 (en) 2016-05-04 2019-03-13 Navigo Proteins GmbH Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker
EP3452492A1 (en) 2016-05-05 2019-03-13 Novartis AG Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
TWI826351B (zh) 2016-05-31 2023-12-21 大陸商鴻運華寧（杭州）生物醫藥有限公司 Ｒ抗體,其藥物組合物及其應用
EP3464375A2 (en) 2016-06-02 2019-04-10 Novartis AG Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
EA201892796A1 (ru) 2016-06-03 2019-06-28 Янссен Байотек, Инк. Связывающиеся с сывороточным альбумином домены фибронектина типа iii
JP2019521105A (ja) 2016-06-07 2019-07-25 ノバルティス アーゲー 補体ｃ５多型を有する患者を治療するための抗ｃ５抗体
WO2017212071A1 (en) 2016-06-10 2017-12-14 Lonza Ltd Method for stabilizing proteins
US11434269B2 (en) 2016-06-15 2022-09-06 Novartis Ag Methods for treating disease using inhibitors of bone morphogenetic protein 6 (BMP6)
US10662235B2 (en) 2016-06-21 2020-05-26 Janssen Biotech, Inc. Cysteine engineered fibronectin type III domain binding molecules
AU2017295886C1 (en) 2016-07-15 2024-05-16 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
TW202508628A (zh) 2016-07-28 2025-03-01 瑞士商諾華公司 嵌合抗原受體及pd-1抑制劑之組合療法
JP2019527696A (ja) 2016-08-01 2019-10-03 ノバルティス アーゲー プロｍ２マクロファージ分子の阻害剤と組み合わせてキメラ抗原受容体を用いる癌の処置
SG11201900528PA (en) 2016-08-02 2019-02-27 Lonza Ag Customizable facility
JP2019528312A (ja) 2016-08-07 2019-10-10 ノバルティス アーゲー ｍＲＮＡ媒介性の免疫化方法
US20190185556A1 (en) 2016-08-08 2019-06-20 Amgen Inc. Method of improving connective tissue attachment using anti-sclerostin antibodies
CN116333065A (zh) 2016-08-11 2023-06-27 纳维格蛋白质有限公司 新型对碱稳定的免疫球蛋白结合蛋白
JP7088932B2 (ja) 2016-09-14 2022-06-21 ヤンセン バイオテツク，インコーポレーテツド Ｂｃｍａ特異的フィブロネクチンｉｉｉ型ドメインを有するキメラ抗原受容体、及びその使用
AU2017331277B2 (en) 2016-09-23 2024-05-30 Marengo Therapeutics, Inc. Multispecific antibody molecules comprising lambda and kappa light chains
CN110225927B (zh) * 2016-10-07 2024-01-12 诺华股份有限公司 用于治疗癌症的嵌合抗原受体
KR20190084264A (ko) 2016-10-25 2019-07-16 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) Cd160 막 횡단 동형체에 결합하는 단클론 항체
WO2018083606A1 (en) 2016-11-01 2018-05-11 Novartis Ag Methods and compositions for enhancing gene editing
JP2020500020A (ja) 2016-11-14 2020-01-09 ノバルティス アーゲー 融合誘導性タンパク質ｍｉｎｉｏｎに関連する組成物、方法、および治療上の使用
WO2018094143A1 (en) 2016-11-17 2018-05-24 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
CN110352068A (zh) 2016-12-02 2019-10-18 南加利福尼亚大学 合成的免疫受体及其使用方法
WO2018106859A1 (en) 2016-12-07 2018-06-14 Ra Pharmaceuticals, Inc. Modulators of complement activity
US10852271B2 (en) 2016-12-14 2020-12-01 Taiwan Semiconductor Manufacturing Co., Ltd. On-chip heater
EP3554561B1 (en) 2016-12-14 2023-06-28 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
EP3554535A4 (en) 2016-12-14 2020-10-21 Janssen Biotech, Inc. PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS
KR102568559B1 (ko) 2016-12-14 2023-08-18 얀센 바이오테크 인코포레이티드 Cd8a-결합 섬유결합소 iii형 도메인
WO2018111340A1 (en) 2016-12-16 2018-06-21 Novartis Ag Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
JOP20190155A1 (ar) 2016-12-21 2019-06-23 Novartis Ag مترافقات عقار جسم مضاد لإزالة خلايا جذعية مكونة للدم
AU2017383537B2 (en) 2016-12-23 2024-10-03 Novartis Ag Methods of treatment with anti-Factor XI/XIa antibodies
CN110325550B (zh) 2016-12-23 2024-03-08 诺华股份有限公司 因子xi抗体和使用方法
WO2018127585A1 (en) 2017-01-06 2018-07-12 Txcell Monospecific regulatory t cell population with cytotoxicity for b cells
EP3346001A1 (en) 2017-01-06 2018-07-11 TXCell Monospecific regulatory t cell population with cytotoxicity for b cells
EP4043485A1 (en) 2017-01-26 2022-08-17 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
TWI786087B (zh) 2017-02-08 2022-12-11 瑞士商諾華公司 Fgf21模擬抗體及其用途
WO2018151820A1 (en) 2017-02-16 2018-08-23 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
US20200048359A1 (en) 2017-02-28 2020-02-13 Novartis Ag Shp inhibitor compositions and uses for chimeric antigen receptor therapy
WO2018158398A1 (en) 2017-03-02 2018-09-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to nectin-4 and uses thereof
CA3054939A1 (en) 2017-03-03 2018-09-07 Seattle Genetics, Inc. Glycan-interacting compounds and methods of use
AU2018226857B2 (en) 2017-03-03 2025-01-02 Obsidian Therapeutics, Inc. Compositions and methods for immunotherapy
JP7341900B2 (ja) 2017-03-03 2023-09-11 オブシディアン セラピューティクス， インコーポレイテッド 免疫療法のためのｃｄ１９組成物及び方法
CN110832075A (zh) 2017-03-22 2020-02-21 诺华股份有限公司 用于免疫肿瘤学的组合物和方法
IL269534B2 (en) 2017-03-30 2025-01-01 Univ Queensland Chimeric molecules and their uses
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
US12134654B2 (en) 2017-04-19 2024-11-05 Marengo Therapeutics, Inc. Multispecific molecules and uses thereof
US11866506B2 (en) 2017-04-21 2024-01-09 Mellitus, Llc Anti-CD59 antibodies
CA3059769A1 (en) 2017-04-28 2018-11-01 Elstar Therapeutics, Inc. Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
AR113224A1 (es) 2017-04-28 2020-02-19 Novartis Ag Conjugados de anticuerpo que comprenden un agonista de sting
CA3064461A1 (en) * 2017-05-31 2018-12-06 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Agriculture And Agri-Food Vaccine against necrotic enteritis in poultry
JP2020522254A (ja) 2017-05-31 2020-07-30 エルスター セラピューティクス， インコーポレイテッド 骨髄増殖性白血病（ｍｐｌ）タンパク質に結合する多特異性分子およびその使用
CA3064163A1 (en) 2017-06-05 2018-12-13 Numab Therapeutics AG Novel anti-cd3 antibodies
WO2018224441A1 (en) 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-cd3 antibodies
WO2018224439A1 (en) 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-hsa antibodies
WO2018229706A1 (en) 2017-06-16 2018-12-20 Novartis Ag Combination therapy for the treatment of cancer
IL270467B2 (en) 2017-06-16 2025-05-01 Lonza Ag A universal self-control platform for a mammalian cell line for the preparation of biological materials
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
DK3642227T3 (da) 2017-06-22 2024-09-02 Adivo Gmbh Hundeantistofbiblioteker
JP7280238B2 (ja) 2017-07-17 2023-05-23 ヤンセン バイオテツク，インコーポレーテツド フィブロネクチンｉｉｉ型ドメインに対する抗原結合領域及びその使用方法
US20200172867A1 (en) 2017-07-19 2020-06-04 Rubius Therapeutics, Inc. Compositions and methods related to multimodal therapeutic cell systems for cardiometabolic disease
EP3654991A1 (en) 2017-07-19 2020-05-27 Rubius Therapeutics, Inc. Compositions and methods related to multimodal therapeutic cell systems for infectious disease
US11472880B2 (en) 2017-08-14 2022-10-18 Morphosys Ag Humanized antibodies for CD3
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
KR102742220B1 (ko) 2017-09-19 2024-12-17 더 유니버시티 오브 브리티쉬 콜롬비아 항-hla-a2 항체 및 그 사용 방법
EP3459968A1 (en) 2017-09-20 2019-03-27 Numab Innovation AG Novel stable antibody variable domain framework combinations
BR112020005519A2 (pt) 2017-09-20 2020-10-27 The University Of British Columbia novos anticorpos anti-hla-a2 e usos dos mesmos
WO2019057982A1 (en) 2017-09-25 2019-03-28 Morphosys Ag TREATMENT OF ATOPIC DERMATITIS
EP3470429A1 (en) 2017-10-10 2019-04-17 Numab Innovation AG Antibodies targeting pdl1 and methods of use thereof
KR20200063147A (ko) 2017-10-10 2020-06-04 누맙 세러퓨틱스 아게 Pdl1 표적화 항체 및 이의 사용 방법
AU2018348431B2 (en) 2017-10-10 2025-10-02 Numab Therapeutics AG Antibodies targeting CD137 and methods of use thereof
EP3470428A1 (en) 2017-10-10 2019-04-17 Numab Innovation AG Antibodies targeting cd137 and methods of use thereof
US11999802B2 (en) 2017-10-18 2024-06-04 Novartis Ag Compositions and methods for selective protein degradation
EP3700933A1 (en) 2017-10-25 2020-09-02 Novartis AG Antibodies targeting cd32b and methods of use thereof
RU2020116579A (ru) 2017-10-25 2021-11-25 Новартис Аг Способы получения клеток, экспрессирующих химерный антигенный рецептор
WO2019089798A1 (en) 2017-10-31 2019-05-09 Novartis Ag Anti-car compositions and methods
EP3706804B1 (en) 2017-11-07 2022-02-23 Navigo Proteins GmbH Fusion proteins with specificity for ed-b and long serum half-life for diagnosis or treatment of cancer
WO2019099639A1 (en) 2017-11-15 2019-05-23 Navartis Ag Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
CN111902427A (zh) 2017-11-22 2020-11-06 诺华股份有限公司 抗因子XI/XIa抗体的逆转结合剂及其用途
WO2019106578A2 (en) 2017-12-01 2019-06-06 Novartis Ag Polyomavirus neutralizing antibodies
EP3720881A1 (en) 2017-12-08 2020-10-14 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
WO2019136432A1 (en) 2018-01-08 2019-07-11 Novartis Ag Immune-enhancing rnas for combination with chimeric antigen receptor therapy
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
WO2019147478A2 (en) 2018-01-18 2019-08-01 California Institute Of Technology Programmable protein circuits in living cells
US11965191B2 (en) 2018-01-18 2024-04-23 California Institute Of Technology Programmable protein circuits in living cells
EP3746116A1 (en) 2018-01-31 2020-12-09 Novartis AG Combination therapy using a chimeric antigen receptor
US12077786B2 (en) 2018-02-02 2024-09-03 Lonza Ltd Methods of cell selection and modifying cell metabolism
WO2019160956A1 (en) 2018-02-13 2019-08-22 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
US11680091B2 (en) 2018-02-23 2023-06-20 The University Of Chicago Methods and composition involving thermophilic fibronectin type III (FN3) monobodies
GB201803563D0 (en) 2018-03-06 2018-04-18 Galapagos Nv Antibodies and pharmaceutical compositions thereof for the treatment of autoimmune skin diseases
WO2019178364A2 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
CN110305211A (zh) 2018-03-20 2019-10-08 鸿运华宁（杭州）生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
US11466079B2 (en) 2018-03-30 2022-10-11 Amgen Inc. C-terminal antibody variants
CN110357959B (zh) 2018-04-10 2023-02-28 鸿运华宁（杭州）生物医药有限公司 Gcgr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
WO2019197678A1 (en) 2018-04-13 2019-10-17 Sangamo Therapeutics France Chimeric antigen receptor specific for interleukin-23 receptor
EP3784351A1 (en) 2018-04-27 2021-03-03 Novartis AG Car t cell therapies with enhanced efficacy
US20210396739A1 (en) 2018-05-01 2021-12-23 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
EP3788138A1 (en) 2018-05-02 2021-03-10 Novartis AG Regulators of human pluripotent stem cells and uses thereof
AU2019270342A1 (en) 2018-05-16 2020-10-29 Morphosys Ag Antibodies targeting glycoprotein VI
EP3801769A1 (en) 2018-05-25 2021-04-14 Novartis AG Combination therapy with chimeric antigen receptor (car) therapies
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
JP7490574B2 (ja) 2018-05-31 2024-05-27 ノバルティス アーゲー Ｂ型肝炎抗体
BR112020024246A2 (pt) 2018-06-01 2021-03-02 University Of Southern California pelo menos um polinucleotídeo recombinante, célula recombinante, receptor de antígeno quimérico, polinucleotídeo que codifica o receptor de antígeno quimérico, vetor, vírus, composição farmacêutica, e, método para tratar câncer
BR112020024351A2 (pt) 2018-06-01 2021-02-23 Novartis Ag moléculas de ligação contra bcma e usos das mesmas
WO2019237035A1 (en) 2018-06-08 2019-12-12 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
EP3806888B1 (en) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
CN119613548A (zh) 2018-06-13 2025-03-14 鸿运华宁（杭州）生物医药有限公司 APJ抗体及其与Elabela的融合蛋白质，以及其药物组合物和应用
CA3100724A1 (en) 2018-06-13 2019-12-19 Novartis Ag B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
UY38265A (es) 2018-06-20 2020-01-31 Novartis Ag Conjugados anticuerpo droga para ablación de células madre hematopoyéticas
TW202011995A (zh) 2018-07-03 2020-04-01 比利時商葛萊伯格有限公司 高濃度液體抗體配製物
AU2019297451A1 (en) 2018-07-03 2021-01-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
JP7455108B2 (ja) 2018-07-10 2024-03-25 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｅ型肝炎ウイルスのＯＲＦ２ｉタンパク質に対する特異性を有する抗体及び診断目的のためのその使用
JP7454546B2 (ja) 2018-07-10 2024-03-22 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｅ型肝炎ウイルスのＯＲＦ２ｉタンパク質に対して特異性を有する抗体及びその診断目的のための使用
US12497624B2 (en) 2018-07-13 2025-12-16 Lonza Ltd Methods for improving production of biological products by reducing the level of endogenous protein
WO2020028616A1 (en) 2018-08-02 2020-02-06 Lonza Ltd Methods for manufacturing recombinant protein comprising a disulfide bond
CA3109253A1 (en) 2018-08-10 2020-02-13 Sangamo Therapeutics France New car constructs comprising tnfr2 domains
US11453893B2 (en) 2018-08-30 2022-09-27 California Institute Of Technology RNA-based delivery systems with levels of control
HRP20251135T1 (hr) 2018-08-31 2025-11-21 Novartis Ag Postupci dobivanja kimernih stanica koje eksprimiraju antigenske receptore
WO2020044252A1 (en) 2018-08-31 2020-03-05 Novartis Ag Dosage regimes for anti-m-csf antibodies and uses thereof
WO2020047449A2 (en) 2018-08-31 2020-03-05 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
WO2020047320A1 (en) 2018-08-31 2020-03-05 California Institute Of Technology Synthetic protein circuits detecting signal transducer activity
WO2020053742A2 (en) 2018-09-10 2020-03-19 Novartis Ag Anti-hla-hbv peptide antibodies
US10955379B2 (en) 2018-09-27 2021-03-23 Taiwan Semiconductor Manufacturing Co., Ltd. Differential sensing with BioFET sensors
AU2019346645A1 (en) 2018-09-27 2021-04-29 Marengo Therapeutics, Inc. CSF1R/CCR2 multispecific antibodies
WO2020069405A1 (en) 2018-09-28 2020-04-02 Novartis Ag Cd22 chimeric antigen receptor (car) therapies
EP3856782A1 (en) 2018-09-28 2021-08-04 Novartis AG Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
JP7592585B2 (ja) 2018-10-04 2024-12-02 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 粘膜炎症性疾患の処置のための方法及び医薬組成物
TWI839395B (zh) 2018-10-09 2024-04-21 瑞士商Ｎｕｍａｂ治療公司 靶向cd137的抗體及其使用方法
EP3636320A1 (en) 2018-10-09 2020-04-15 Numab Therapeutics AG Antibodies targeting cd137 and methods of use thereof
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
US20210386788A1 (en) 2018-10-24 2021-12-16 Obsidian Therapeutics, Inc. Er tunable protein regulation
WO2020089815A1 (en) 2018-10-31 2020-05-07 Novartis Ag Antibody conjugates comprising sting agonist
WO2020092617A1 (en) 2018-10-31 2020-05-07 Novartis Ag Dc-sign antibody conjugates comprising sting agonists
EP3873532A1 (en) 2018-10-31 2021-09-08 Novartis AG Dc-sign antibody drug conjugates
WO2020102565A2 (en) 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Systems and methods for nondestructive testing of gametes
EP3886876A1 (en) 2018-11-30 2021-10-06 Celularity Inc. Placenta-derived allogeneic car-t cells and uses thereof
JP2022513708A (ja) 2018-12-05 2022-02-09 モルフォシス・アーゲー 多重特異性抗原結合分子
SG11202104012QA (en) 2018-12-14 2021-05-28 Morphosys Ag Antibody formulations
MA54501A (fr) 2018-12-18 2021-10-27 Navigo Proteins Gmbh Nouvelles protéines de liaison spécifiques de folr1 pour le diagnostic et le traitement du cancer
TW202039586A (zh) 2018-12-18 2020-11-01 瑞士商諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
WO2020128863A1 (en) 2018-12-19 2020-06-25 Novartis Ag Anti-tnf-alpha antibodies
US11779649B2 (en) 2018-12-21 2023-10-10 Novartis Ag Antibodies to PMEL17 and conjugates thereof
CN111349550B (zh) * 2018-12-24 2022-12-23 中粮生物科技股份有限公司 一种高通量发酵好氧菌种的装置和方法以及他们的应用
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
EP3908653A4 (en) 2019-01-10 2022-11-02 California Institute of Technology A synthetic system for tunable thresholding of protein signals
US12410260B2 (en) 2019-01-11 2025-09-09 The University Of North Carolina At Chapel Hill Highly modular biepitopic and bispecific CAR-T cells for cancer immunotherapy
EP3689907A1 (en) 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
IL320091A (en) 2019-01-31 2025-06-01 Numab Therapeutics AG Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof
GB2598218B (en) 2019-02-21 2024-05-08 Marengo Therapeutics Inc Anti-TCR antibody molecules and uses thereof
SG11202109061YA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Multifunctional molecules that bind to t cell related cancer cells and uses thereof
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
AU2020224680B2 (en) 2019-02-21 2025-06-19 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cells and uses thereof to treat autoimmune disorders
EP3927746A1 (en) 2019-02-21 2021-12-29 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
US20220088075A1 (en) 2019-02-22 2022-03-24 The Trustees Of The University Of Pennsylvania Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
US20220152150A1 (en) 2019-02-25 2022-05-19 Novartis Ag Mesoporous silica particles compositions for viral delivery
AU2020235865A1 (en) 2019-03-08 2021-09-23 Obsidian Therapeutics, Inc. Human carbonic anhydrase 2 compositions and methods for tunable regulation
SG11202108761YA (en) 2019-03-14 2021-09-29 Morphosys Ag Antibodies targeting c5ar
EP3938394A1 (en) 2019-03-15 2022-01-19 MorphoSys AG Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease
EP3942025A1 (en) 2019-03-21 2022-01-26 Novartis AG Car-t cell therapies with enhanced efficacy
WO2020206248A1 (en) 2019-04-03 2020-10-08 Precision Biosciences, Inc. Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir)
CA3136265A1 (en) 2019-04-05 2020-10-08 Precision Biosciences, Inc. Methods of preparing populations of genetically-modified immune cells
US20220168389A1 (en) 2019-04-12 2022-06-02 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
AU2020257748A1 (en) 2019-04-19 2021-11-18 Chugai Seiyaku Kabushiki Kaisha Chimeric receptor recognizing modification site of antibody
EP3959320A1 (en) 2019-04-24 2022-03-02 Novartis AG Compositions and methods for selective protein degradation
WO2020223445A1 (en) 2019-04-30 2020-11-05 Senti Biosciences, Inc. Chimeric receptors and methods of use thereof
US20220242952A1 (en) 2019-05-03 2022-08-04 Morphosys Ag Anti-cd19 therapy in patients having a limited number of nk cells
WO2020227515A1 (en) 2019-05-07 2020-11-12 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
EP3972651A2 (en) 2019-05-20 2022-03-30 Novartis AG Mcl-1 inhibitor antibody-drug conjugates and methods of use
CN119613486A (zh) 2019-05-20 2025-03-14 诺华股份有限公司 具有包含亲水性基团的接头的抗体药物缀合物
CN113874398B (zh) 2019-05-21 2025-08-01 诺华股份有限公司 Cd19结合分子及其用途
KR20220010743A (ko) 2019-05-21 2022-01-26 노파르티스 아게 Bcma에 대한 삼중특이적 결합 분자 및 이의 용도
WO2020236797A1 (en) 2019-05-21 2020-11-26 Novartis Ag Variant cd58 domains and uses thereof
AR119267A1 (es) 2019-06-12 2021-12-09 Novartis Ag Anticuerpos de receptor de péptido natriurético 1 y métodos de uso
CA3144324A1 (en) 2019-06-24 2020-12-30 Novartis Ag Dosing regimen and combination therapies for multispecific antibodies targeting b-cell maturation antigen
CN112239507A (zh) 2019-07-17 2021-01-19 鸿运华宁（杭州）生物医药有限公司 ETA抗体与TGF-β Trap的融合蛋白质，以及其药物组合物和应用
EP4004216A1 (en) 2019-07-25 2022-06-01 Precision BioSciences, Inc. Compositions and methods for sequential stacking of nucleic acid sequences into a genomic locus
WO2021030303A1 (en) 2019-08-12 2021-02-18 Voyager Therapeutics, Inc. High-sensitivity immunoassay for the detection of frataxin in biofluids
AU2020333851A1 (en) 2019-08-20 2022-03-31 Precision Biosciences, Inc. Lymphodepletion dosing regimens for cellular immunotherapies
EP4017870B1 (en) * 2019-08-23 2025-07-30 United States Government as represented by the Department of Veterans Affairs Compositions and methods for treating and preventing autoimmune induced cardiac long qt syndrome
EP4025604A1 (en) 2019-09-04 2022-07-13 Institut National de la Santé et de la Recherche Médicale (INSERM) Antibodies specific for il20-rb and uses thereof for the treatment of acute exacerbation of chronic obstructive pulmonary disease
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
CN114502590A (zh) 2019-09-18 2022-05-13 诺华股份有限公司 Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
CN112521501A (zh) 2019-09-18 2021-03-19 鸿运华宁（杭州）生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
EP3800201A1 (en) 2019-10-01 2021-04-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Cd28h stimulation enhances nk cell killing activities
US11781138B2 (en) 2019-10-14 2023-10-10 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
WO2021076543A1 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Epcam binding fibronectin type iii domains
EP4045061A4 (en) 2019-10-14 2024-04-17 ARO Biotherapeutics Company CD71-BINDING FIBRONECTIN TYPE III DOMAINS
EP3808766A1 (en) 2019-10-15 2021-04-21 Sangamo Therapeutics France Chimeric antigen receptor specific for interleukin-23 receptor
US10984211B1 (en) 2019-10-18 2021-04-20 Taiwan Semiconductor Manufacturing Co., Ltd. Semiconductor device with bioFET and biometric sensors
WO2021087305A1 (en) 2019-10-30 2021-05-06 Precision Biosciences, Inc. Cd20 chimeric antigen receptors and methods of use for immunotherapy
EP4051710B1 (en) 2019-10-31 2025-11-26 Incyte Corporation Anti-tumor combination therapy comprising anti-cd19 antibody and gamma delta t-cells
AU2020376305A1 (en) 2019-10-31 2022-05-12 Incyte Corporation Anti-CD19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma
WO2021094461A1 (en) 2019-11-14 2021-05-20 Lonza Ltd Methods of cell selection
BR112022009598A2 (pt) 2019-11-18 2022-08-16 Janssen Biotech Inc Vacinas baseadas em calr e jak2 mutantes e uso dos mesmos
IL292924A (en) 2019-11-26 2022-07-01 Novartis Ag Chimeric antigen receptors cd19 and cd22 and their uses
CN114761037A (zh) 2019-11-26 2022-07-15 诺华股份有限公司 结合bcma和cd19的嵌合抗原受体及其用途
CN115397442A (zh) 2019-12-04 2022-11-25 细胞结构公司 胎盘源性同种异体car-t细胞及其用途
US12162953B2 (en) 2019-12-06 2024-12-10 Yale University Enhanced targeting platform
CA3160096A1 (en) 2019-12-06 2021-06-10 Bruce J. Mccreedy Jr. Methods for cancer immunotherapy
US20230040928A1 (en) 2019-12-09 2023-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to her4 and uses thereof
US20230020548A1 (en) 2019-12-09 2023-01-19 Novartis Ag Anti-interleukin 1 beta antibodies for treatment of sickle cell disease
JP7703541B2 (ja) 2019-12-18 2025-07-07 アロ・バイオセラピューティクス・カンパニー 血清アルブミン結合性フィブロネクチンｉｉｉ型ドメインおよびその使用
EP4084821A4 (en) 2020-01-03 2024-04-24 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
EP4084823A4 (en) 2020-01-03 2024-05-15 Marengo Therapeutics, Inc. ANTI-TCR ANTIBODY MOLECULES AND THEIR USES
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
WO2021163618A1 (en) 2020-02-14 2021-08-19 Novartis Ag Method of predicting response to chimeric antigen receptor therapy
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
EP4111168A1 (en) 2020-02-25 2023-01-04 Becton Dickinson and Company Bi-specific probes to enable the use of single-cell samples as single color compensation control
IL295878A (en) 2020-02-27 2022-10-01 Novartis Ag Methods for producing cells expressing a chimeric antigen receptor
TW202146441A (zh) 2020-02-27 2021-12-16 瑞士商諾華公司 製備表現嵌合抗原受體的細胞之方法
WO2021188599A1 (en) 2020-03-16 2021-09-23 University Of Southern California Novel antigen binding domains and synthetic antigen receptors incorporating the same
IL296546A (en) 2020-03-20 2022-11-01 Inst Nat Sante Rech Med Chimeric receptor for human cd45rc-specific antigen and its uses
JP2023520773A (ja) 2020-03-27 2023-05-19 ノバルティス アーゲー 増殖性疾患及び自己免疫疾患を治療するための二重特異性組合せ治療
CA3174339A1 (en) 2020-04-07 2021-10-14 Xin Du Anti-tmprss6 antibodies and uses thereof
EP4135841A1 (en) 2020-04-15 2023-02-22 Voyager Therapeutics, Inc. Tau binding compounds
WO2021211776A1 (en) 2020-04-15 2021-10-21 California Institute Of Technology Thermal control of t-cell immunotherapy through molecular and physical actuation
WO2021217085A1 (en) 2020-04-24 2021-10-28 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
US20230181756A1 (en) 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
WO2021228956A1 (en) 2020-05-12 2021-11-18 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas
IL298114A (en) 2020-05-12 2023-01-01 Lyell Immunopharma Inc Chimeric antigen receptor spacers
PL4153242T3 (pl) 2020-05-19 2024-09-23 Les Laboratoires Servier Para-amino-benzylowe związki łączące, sposób ich otrzymywania oraz ich zastosowanie w koniugatach
KR20230024967A (ko) 2020-06-11 2023-02-21 노파르티스 아게 Zbtb32 억제제 및 이의 용도
KR20230024984A (ko) 2020-06-12 2023-02-21 엔카르타, 인크. Cd70-지시 암 면역요법용 유전적으로 변형된 자연 살해 세포
EP4168449A1 (en) 2020-06-22 2023-04-26 MorphoSys AG Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirpa-cd47 innate immune checkpoint
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
PH12023550015A1 (en) 2020-07-16 2024-03-11 Novartis Ag Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
EP3943097A1 (en) 2020-07-24 2022-01-26 AB2 Bio SA Car-t cell therapy
WO2022035793A1 (en) 2020-08-10 2022-02-17 Precision Biosciences, Inc. Antibodies and fragments specific for b-cell maturation antigen and uses thereof
IL300489A (en) 2020-08-21 2023-04-01 Novartis Ag Compositions and methods for in vivo production of CAR expressing cells
WO2022046922A2 (en) 2020-08-26 2022-03-03 Marengo Therapeutics, Inc. Antibody molecules that bind to nkp30 and uses thereof
CA3190755A1 (en) 2020-08-26 2022-03-03 Andreas Loew Multifunctional molecules that bind to calreticulin and uses thereof
EP4204458A4 (en) 2020-08-26 2024-10-09 Marengo Therapeutics, Inc. METHODS FOR DETECTION OF TRBC1 OR TRBC2
WO2022047259A1 (en) 2020-08-28 2022-03-03 California Institute Of Technology Synthetic mammalian signaling circuits for robust cell population control
JP7788106B2 (ja) * 2020-08-31 2025-12-18 国立大学法人東海国立大学機構 フィブロネクチンｉｉｉ型ドメイン骨格を含むポリペプチド
EP4217391A1 (en) 2020-09-24 2023-08-02 MorphoSys AG Novel human antibodies binding to human cd3 epsilon
WO2022076547A1 (en) 2020-10-07 2022-04-14 Precision Biosciences, Inc. Lipid nanoparticle compositions
WO2022097090A1 (en) 2020-11-05 2022-05-12 Novartis Ag Dosing regimen for combination therapies with multispecific antibodies targeting b-cell maturation antigen and gamma secretase inhibitors
JP2023548529A (ja) 2020-11-06 2023-11-17 ノバルティス アーゲー Ｃｄ１９結合分子及びその使用
CN116390933A (zh) 2020-11-06 2023-07-04 诺华股份有限公司 治疗b细胞恶性肿瘤的抗cd19剂和b细胞靶向剂组合疗法
CN116472288A (zh) 2020-11-06 2023-07-21 诺华股份有限公司 抗体Fc变体
AU2021378316A1 (en) 2020-11-13 2023-06-01 Novartis Ag Combination therapies with chimeric antigen receptor (car)-expressing cells
EP4251648A2 (en) 2020-11-24 2023-10-04 Novartis AG Anti-cd48 antibodies, antibody drug conjugates, and uses thereof
EP4251209A1 (en) 2020-11-24 2023-10-04 Novartis AG Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
US20240042051A1 (en) 2020-11-24 2024-02-08 Francesca Rocchetti Mcl-1 inhibitor antibody-drug conjugates and methods of use
JP2023551559A (ja) 2020-12-04 2023-12-08 モルフォシス・アーゲー 抗ｃｄ１９併用療法
EP4259661A1 (en) 2020-12-14 2023-10-18 Novartis AG Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof
CA3205586A1 (en) 2020-12-16 2022-06-23 Voyager Therapeutics, Inc. Tau binding compounds
US20250127811A1 (en) 2021-01-28 2025-04-24 Precision Biosciences, Inc. Modulation of tgf beta signaling in genetically-modified eukaryotic cells
WO2022171736A1 (en) 2021-02-10 2022-08-18 Limagrain Europe Multiplex targeted recombinations for trait introgression applications
WO2022182891A1 (en) 2021-02-25 2022-09-01 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
CN115141276A (zh) 2021-03-31 2022-10-04 鸿运华宁（杭州）生物医药有限公司 一种能与人内皮素受体特异性结合的抗体及其在糖尿病肾病和慢性肾病治疗中的应用
BR112023020832A2 (pt) 2021-04-08 2023-12-19 Marengo Therapeutics Inc Moléculas multifuncionais ligadas a tcr e seus usos
MX2023012128A (es) 2021-04-14 2024-01-11 Aro Biotherapeutics Company Dominios tipo iii de la fibronectina que se unen a cd71.
US12239710B2 (en) 2021-04-14 2025-03-04 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
CA3235132A1 (en) 2021-04-16 2022-10-20 Novartis Ag Antibody drug conjugates and methods for making thereof
WO2022254337A1 (en) 2021-06-01 2022-12-08 Novartis Ag Cd19 and cd22 chimeric antigen receptors and uses thereof
WO2022263057A1 (en) 2021-06-18 2022-12-22 Advancecor Gmbh Use of a pharmaceutical composition
JP2024525475A (ja) 2021-06-29 2024-07-12 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド タノトランスミッションを促進するように操作された免疫細胞及びその使用
CN117642431B (zh) 2021-07-13 2025-07-15 迈威(美国)生物治疗有限公司 抗c1s抗体和其用途
EP4377347A1 (en) 2021-07-27 2024-06-05 MorphoSys AG Combinations of antigen binding molecules
CA3229746A1 (en) 2021-08-20 2023-02-23 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
US20250223376A1 (en) 2021-09-20 2025-07-10 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
GB202113674D0 (en) 2021-09-24 2021-11-10 Reflection Therapeutics Ltd Targeted cell therapies
GB202113673D0 (en) 2021-09-24 2021-11-10 Reflection Therapeutics Ltd Targeted cell therapies
WO2023064872A1 (en) 2021-10-14 2023-04-20 Precision Biosciences, Inc. Combinations of anti-bcma car t cells and gamma secretase inhibitors
EP4423131A1 (en) 2021-10-27 2024-09-04 Granite Bio AG Antibodies targeting ccr2
WO2023081767A1 (en) 2021-11-05 2023-05-11 Precision Biosciences, Inc. Methods for immunotherapy
WO2023091910A1 (en) 2021-11-16 2023-05-25 Precision Biosciences, Inc. Methods for cancer immunotherapy
CN118632860A (zh) 2021-11-24 2024-09-10 诺华股份有限公司 腺相关病毒转导调节剂及其用途
WO2023108150A1 (en) 2021-12-10 2023-06-15 Precision Biosciences, Inc. Methods for cancer immunotherapy
EP4453224A1 (en) 2021-12-21 2024-10-30 Universität Zürich Adenoviral vectors
US20250138026A1 (en) 2022-02-01 2025-05-01 Institut National de la Santé et de la Recherche Médicale Method for diagnosing collagen degradation associated disease
AU2023222463A1 (en) 2022-02-18 2024-08-08 Zoetis Services Llc Feline antibody library
JP2025508472A (ja) 2022-02-25 2025-03-26 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） メタロプロテアーゼによるｃｄ９５ｌの切断を阻止するための抗体
US20250388932A1 (en) 2022-03-11 2025-12-25 Institut National De La Sante Et De La Recherche Medicale Nucleic acid system to specifically reprogram b and t cells and uses thereof
CN118922448A (zh) 2022-03-22 2024-11-08 莫佛塞斯公司 Cd3特异性的去免疫抗体
US20250215452A1 (en) 2022-03-25 2025-07-03 Universität Zürich Adenoviral Mediated Targeting of Activated Immune Cells
TW202405009A (zh) 2022-03-30 2024-02-01 瑞士商諾華公司 使用抗利尿鈉肽受體１（ｎｐｒ１）抗體治療障礙之方法
CN119095619A (zh) 2022-04-14 2024-12-06 诺华股份有限公司 抗cd19药剂的剂量方案及其用途
CA3255627A1 (en) 2022-05-06 2023-11-09 Novartis Ag NEW VP2 FUSION POLYPEPTIDES OF RECOMBINANT AAV
US20250295809A1 (en) 2022-05-13 2025-09-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
EP4525925A1 (en) 2022-05-20 2025-03-26 Novartis AG Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
WO2023225359A1 (en) 2022-05-20 2023-11-23 Novartis Ag Antibody-drug conjugates of antineoplastic compounds and methods of use thereof
CA3256012A1 (en) 2022-05-20 2023-11-23 Les Laboratoires Servier ANTIBODY-DRUG CONJUGATES, MET INHIBITORS BCL-XL, AND THEIR METHODS OF USE
US20250243263A1 (en) 2022-06-22 2025-07-31 Voyager Therapeutics, Inc. Tau binding compounds
WO2024008910A1 (en) 2022-07-07 2024-01-11 Cimeio Therapeutics Ag Antibodies targeting cd117
WO2024044770A1 (en) 2022-08-26 2024-02-29 Core Biotherapeutics, Inc. Oligonucleotides for the treatment of breast cancer
WO2024047114A1 (en) 2022-08-31 2024-03-07 Universität Zürich Adenoviral-based in situ delivery of bispecific t cell engagers
JP2025531832A (ja) 2022-09-08 2025-09-25 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ＬＴＢＰ２（潜在的形質転換増殖因子β結合タンパク質２）に対する特異性を有する抗体及びその使用
EP4585617A1 (en) 2022-09-08 2025-07-16 Gmax Biopharm LLC Gipr antibody, fusion protein thereof with fgf21, pharmaceutical composition thereof, and use thereof
CA3266790A1 (en) 2022-09-15 2024-03-21 Voyager Therapeutics, Inc. TAU PROTEIN BINDING COMPOUNDS
EP4587047A1 (en) 2022-09-15 2025-07-23 Novartis AG Treatment of autoimmune disorders using chimeric antigen receptor therapy
EP4598945A1 (en) 2022-10-07 2025-08-13 Universität Zürich Paracrine adenoviral delivery of biomolecules
EP4608861A1 (en) 2022-10-24 2025-09-03 F. Hoffmann-La Roche AG Predicting response to il-6 antagonists
WO2024099990A1 (en) 2022-11-07 2024-05-16 Leibniz-Institut Für Immuntherapie (Lit) TGF-ß SWITCH RECEPTOR CAR T CELLS
KR20250112850A (ko) 2022-11-28 2025-07-24 노파르티스 아게 Pcta 유도체, 이의 접합체 및 이의 용도
EP4626401A1 (en) 2022-12-01 2025-10-08 Generation Bio Co. Stealth lipid nanoparticle compositions for cell targeting
EP4637928A1 (en) 2022-12-23 2025-10-29 Cimeio Therapeutics AG Antibodies targeting cd45
EP4646223A1 (en) 2023-01-05 2025-11-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for the human t cell receptor alpha constant region gene
AU2024209632A1 (en) 2023-01-20 2025-05-08 Mabwell Therapeutics, Inc. ANTI-AMYLOID β PROTOFIBRIL/OLIGOMER ANTIBODIES AND USES THEREOF
WO2024170543A1 (en) 2023-02-14 2024-08-22 Institut National de la Santé et de la Recherche Médicale Anti-cd44 antibodies and uses thereof
KR20250160354A (ko) 2023-03-10 2025-11-12 노파르티스 아게 Panras 억제제 항체-약물 콘쥬게이트 및 이의 사용 방법
IL323042A (en) 2023-03-27 2025-10-01 Adivo Gmbh Anti-dog PD-L1 antibodies
WO2024236163A1 (en) 2023-05-17 2024-11-21 Morphosys Ag T cell receptor beta constant region 2 (trbc2) antibodies
WO2024236167A1 (en) 2023-05-17 2024-11-21 Morphosys Ag Il-13 receptor alpha 2 binding polypeptides
CN121399160A (zh) 2023-05-29 2026-01-23 花岗岩生物股份公司 靶向ccr2的抗体
TW202448953A (zh) 2023-06-01 2024-12-16 法商皮爾法伯製藥公司 用於腫瘤及轉移之治療的基於沉默抗體的抗met建構物
WO2024261027A1 (en) 2023-06-19 2024-12-26 Vector Biopharma Ag Il-7-retargeting of adenoviruses for cell specific infection
WO2025003511A1 (en) 2023-06-30 2025-01-02 Morphosys Ag Dual-targeting of flt3 and cd123 co-expressing tumor cells by functional complementation of cycat® halfbody molecules
WO2025036892A1 (en) 2023-08-14 2025-02-20 Morphosys Ag Cycat halfbody molecules comprising sterically occluding moieties
WO2025061682A1 (en) 2023-09-21 2025-03-27 Universität Zürich Adenoviral targeting of dendritic cells
TW202521582A (zh) 2023-09-28 2025-06-01 瑞士商六峰生物股份有限公司 靶向ActRIIA及ActRIIB之抗體
WO2025082777A1 (en) 2023-10-17 2025-04-24 Morphosys Ag Dual-targeting of muc16 and mesothelin co-expressing tumor cells by functional complementation of cycat® halfbody molecules
WO2025087681A1 (en) 2023-10-26 2025-05-01 Morphosys Ag Bispecific antibodies against cd3 and cd20
WO2025111431A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd7 antibody-drug conjugates and methods of use thereof
WO2025111450A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd74 antibody-drug conjugates and methods of use thereof
WO2025109043A2 (en) 2023-11-22 2025-05-30 Institut National de la Santé et de la Recherche Médicale Use of neutralizing anti-agr2 antibodies for preventing resistance to chemotherapy
WO2025120015A1 (en) 2023-12-06 2025-06-12 Institut National de la Santé et de la Recherche Médicale Cd5 targeting antibodies with depleting and t or b-cell activation effects
WO2025129120A2 (en) 2023-12-15 2025-06-19 Port Therapeutics, Inc. Use of thermal bioswitches for treating autoimmune diseases
WO2025129085A1 (en) 2023-12-15 2025-06-19 Port Therapeutics, Inc. Use of thermal bioswitches in aav-based gene therapy
WO2025224297A1 (en) 2024-04-26 2025-10-30 Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to tgfbi and uses thereof
WO2025242732A1 (en) 2024-05-21 2025-11-27 Institut National de la Santé et de la Recherche Médicale Pan antibodies against sars-cov-2 spike protein and uses thereof for therapeutical purposes
WO2025247918A1 (en) 2024-05-28 2025-12-04 Institut National de la Santé et de la Recherche Médicale ANTI-IFN-α2 MONOCLONAL ANTIBODIES
WO2025247913A1 (en) 2024-05-28 2025-12-04 Institut National de la Santé et de la Recherche Médicale Anti-ifn-omega1 monoclonal antibodies
WO2025247917A1 (en) 2024-05-28 2025-12-04 Institut National de la Santé et de la Recherche Médicale ANTI-IFN-α2 AND ANTI-IFN-ω1 MONOCLONAL ANTIBODIES
WO2025247924A1 (en) 2024-05-28 2025-12-04 Institut National de la Santé et de la Recherche Médicale ANTI-IFN-α2 MONOCLONAL ANTIBODIES
WO2025250739A1 (en) 2024-05-31 2025-12-04 Janssen Biotech, Inc. Chimeric antigen receptor with spacer domains derived from human igg
WO2025259600A2 (en) 2024-06-10 2025-12-18 University Of Rochester Brain protein targets for the treatment of migraine
WO2025257181A1 (en) 2024-06-11 2025-12-18 Institut National de la Santé et de la Recherche Médicale Antibodies targeting trans-active response dna-binding protein-43 (tdp-43)
WO2026011013A1 (en) 2024-07-02 2026-01-08 Epibiologics, Inc. Binding agents and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963355A (en) 1986-06-23 1990-10-16 Igen, Inc. Production of antibody catalysts
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5258289A (en) 1990-09-05 1993-11-02 Davis Claude G Method for the selecting of genes encoding catalytic antibodies
US6955900B1 (en) 1993-02-02 2005-10-18 The Scripps Research Institute Methods for producing polypeptide binding sites, monoclonal antibodies and compositions thereof
CA2159724C (en) 1993-04-09 2002-02-26 Claude Geoffrey Davis Selecting genes encoding catalytic antibodies
WO1995027045A1 (en) 1994-03-30 1995-10-12 Igen, Inc. The isolation and production of catalytic antibodies using phage technology
US6348584B1 (en) 1996-10-17 2002-02-19 John Edward Hodgson Fibronectin binding protein compounds
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
JP4562286B2 (ja) 1998-12-10 2010-10-13 ブリストル−マイヤーズ スクウィブ カンパニー 抗体模倣物および他の結合タンパク質のタンパク質骨格
US6391855B1 (en) 1999-06-02 2002-05-21 Adherex Technologies, Inc. Compounds and methods for modulating junctional adhesion molecule-mediated functions
AU2001277867B2 (en) 2000-07-11 2006-12-07 Research Corporation Technologies, Inc. Artificial antibody polypeptides
US7598352B2 (en) 2000-11-17 2009-10-06 University Of Rochester Method of identifying polypeptide monobodies which bind to target proteins and use thereof
AU2003243436A1 (en) 2002-06-06 2003-12-22 Shohei Koide Reconstituted polypeptides
AU2003244817B2 (en) * 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
US20040081648A1 (en) 2002-08-27 2004-04-29 Afeyan Noubar B. Adzymes and uses thereof
WO2004029224A2 (en) 2002-09-30 2004-04-08 Compound Therapeutics, Inc. Methods of engineering spatially conserved motifs in polypeptides
AU2004296376B2 (en) 2003-12-05 2010-03-04 Bristol-Myers Squibb Company Inhibitors of type 2 vascular endothelial growth factor receptors

Also Published As

Publication number Publication date
US7981620B2 (en) 2011-07-19
EP0985039B1 (en) 2008-02-20
US20100099168A1 (en) 2010-04-22
US6673901B2 (en) 2004-01-06
US7078490B2 (en) 2006-07-18
US8062858B2 (en) 2011-11-22
CA2293632A1 (en) 1998-12-17
EP1958962A3 (en) 2013-05-01
US6462189B1 (en) 2002-10-08
EP1958962A2 (en) 2008-08-20
US20090270597A1 (en) 2009-10-29
US20030134386A1 (en) 2003-07-17
US6703199B1 (en) 2004-03-09
JP3614866B2 (ja) 2005-01-26
DE69839147D1 (de) 2008-04-03
US7119171B2 (en) 2006-10-10
US7153661B2 (en) 2006-12-26
WO1998056915A3 (en) 1999-03-04
US20120135516A1 (en) 2012-05-31
ES2301198T3 (es) 2008-06-16
US20030170753A1 (en) 2003-09-11
US20020019517A1 (en) 2002-02-14
EP2380906A2 (en) 2011-10-26
AU729035B2 (en) 2001-01-25
DE69839147T2 (de) 2009-02-19
WO1998056915A2 (en) 1998-12-17
EP0985039A2 (en) 2000-03-15
US20060257953A1 (en) 2006-11-16
US20060240018A1 (en) 2006-10-26
ATE386802T1 (de) 2008-03-15
US9127090B2 (en) 2015-09-08
CA2293632C (en) 2011-11-29
AU7959698A (en) 1998-12-30
US20030108948A1 (en) 2003-06-12
US7858090B2 (en) 2010-12-28
US8106162B2 (en) 2012-01-31
JP2001500531A (ja) 2001-01-16

Similar Documents

Publication Publication Date Title
DK0985039T3 (da) Kunstige antistof-polypeptider
WO2002004523A3 (en) Artificial antibody polypeptides
ATE110773T1 (de) Verfahren zur züchtung rekombinanter zellen.
ATE313633T1 (de) Expressionsvektoren die für bispezifische proteine kodieren, und verfahren zur herstellung von biologisch-aktiven bispezifischen fusionsproteine in zellen von säugertieren
ATE145239T1 (de) Rns-katalysator zur spaltung von spezifischen rns-sequenzen
FI883082A0 (fi) Konstruering av syntetisk dna och dess anvaendning i syntes av stora polypeptider.
WO2000006726A3 (en) Delta-related polypeptides
ATE152124T1 (de) Wachstumsfaktor aus parenchymalen lebenszellen, dafür kodierendes gen, verfahren zur herstellung dieses faktors und transformanten
EP0821064A3 (en) Recombinant fructosyl amino acid oxidase
EP0494702A3 (en) Production of factor xiiia by gene technology
AU6661490A (en) Novel polypeptides, the DNA sequences allowing their expression, method of preparation, and utilization
DE69736389T8 (de) Proteine mit zellulase-aktivitäten und prozess für ihre herstellung
DE69430975D1 (de) Verfahren zur Herstellung von Proteinen
EP0333587B1 (en) Method for purifying and isolating carboxyl-terminal peptides
ATE102994T1 (de) Verfahren zur herstellung von proteinen.
ATE345382T1 (de) 2,6-beta-d-fruktanhydrolase enzym und verfahren zu dessen verwendung
EP0745674A3 (en) Helicobacter polypeptides, their production and use
WO1999029724A3 (en) Dna encoding pasteurella multocida outer membrane protein
ATE445017T1 (de) Methode zur herstellung eines polypeptides, einer rna oder einer anderen verbindung in tumorgewebe
US6762041B2 (en) Method for isotope labeling of protein with enzyme
EP0289187A3 (en) Vinyl substituted radiohalogen conjugates for protein labeling
WO1999023228B1 (en) Svph1-26 dna and polypeptides
RU2000132224A (ru) Новый способ клонирования генов
DE69333106D1 (de) Polypeptidproduktion
ATE153070T1 (de) Verfahren zur herstellung eines vollendeten polypeptids durch faktor-xa enzymatische spaltung